Member Info for ratcliffewriter

I thought it was that they didn't have authority to place spontaneously, but a placing can be put to an EGM for approval or otherwise by shareholders?

Paternoster - No, I was referring to VAL, that's why I posted on the VAL board. Since you mention them, you are probably aware that sclp have just raised 12 million at about 5 percent discount, to add to 20 million in the bank, and an 85 percent orr in stage 4 cancer patients and a number of institutional investors. But that's not relevant to VAL's predicament is it? So maybe stick with me deciding whether VAL is investable or not. Keep focused.

It's looking like a late afternoon RNS tomorrow. Around 4.29pm. I would hope not, for the sake of so many here, but we shall see.

That very much depends on the company you keep. With all due respect Fred.

Just a couple of small but significant details need adding to your last - "Surely Inophea is generating some decent revenue now" - surely Suzy would have mentioned that in the video the other day if it were even on the horizon?

And as for 'The 201 money will come in handy' - with all due respect, what 201 money? Seem to be a few large 'IF's missing there.

Given that a placing at 11p hasn't been fully finished, and the open offer to shareholders hasn't even had the paperwork sent out yet, the sp reaction is very encouraging with some regular 100k buys cropping up along the way. Just goes to show that a healthy cash balance says a great deal. Back it with VERY promising trial results and the future looks quite interesting. Imo....

The fact remains that today's RNS provides no cash of any significance whatsoever, so the question remains 'where is the urgently needed money coming from?'

Is the next RNS a shed load of cash from TheoremRx or a placing with Suzy saying 'we are very disappointed that euda/TheoremRx merger hasn't worked in our favour, and this placing is essential to provide working capital (i.e. salaries for the bod) until the 401 "deal" bears fruit.'

Place your bets....

I'm pretty sure I will.

Maybe, but you could also argue that as the man who didn't invest 100k and as a consequence still have it, that also says a lot.

I'm not suggesting anyone invest, not invest, buy more or sell up on anything other than their own research, but the greater the percentage of one's wealth you invest, the more rigorously and dispassionately you should research, i would suggest. I'm just exploring facts versus conjecture.

As far as 'the professor' is concerned, anyone who is into Val for a seven figure sum is surely trapped and unable to get out without crashing the share price and their own remaining investment as a consequence. And it also depends what fraction of one's fortune a million quid might be. For me, 100k is a maximum in one company, but for others a million may be an amount they'd be happy to lose or take a big hit on.

As ever, just putting out food for thought - not something to be scared of, although it will say a lot about attitudes and fear if this post is still here by 9am tomorrow.

It's a matter of looking for a business case on which to invest - I've been watching for years, and had I invested 100k before the last consolidation it would have become 800 quid, so I would suggest that my intuition has saved me 96,400 pounds, wouldn't you?

Believe me, I'm not 'saving you' from anything. I watched John Gilchrist post here and thought he was a little blinkered, then as I understand it he took his own life as a consequence (correct me if I'm wrong) - if that were the case, I'd like to think I am a little more prudent before pitching in wholesale.

As for 'the statement from EUDA clearly indicates that they felt TRX has access to significant funds. No IFS to that statement. RNS also confirms Valirx would get paid when the sub license is signed. I think everyone knows that.'

Look closely at what you yourself say - 'EUDA....indicates...they felt', and 'when the sub licence is signed'....When? You mean 'if', or 'assuming.'

This is very much about business.

It's not science, it's business. Everything hangs on numerous interconnected 'ifs.' Should one 'if' fail, the whole thing collapses like a house of cards.

You say 'TRX obviously sees significant potential in 201 to be funding 10s million for trials as and when it is confirmed' - but theoremrx aren't funding '10s of millions', they're trying and so far failing for 2 years to raise under 2 million. And it isn't 'when it is confirmed', it's IF. And that 'IF' has looked ever larger and more shaky as time passes, hasn't it?

'Nothing to say with the deal we should not be worth...'

With all due respect, what deal?

And the failure you contemplate would likely not result in a buyout, it would more likely result in oblivion don't you think? This company is currently clinging on by its fingernails as far as I can see. Wouldn't you agree, being realistic?

Just ticked up a little bit more. But it's only just gone 9.30 so relax. Better to say 'it's only just turned December. (Unless you want trader volatility which is a different approach altogether)

Indeed - 1.5 million in the first hour or so, above the placing price. Pretty muted, sure...

'EUDA need TRx. Without the merger, EUDA will get delisted in next 12 months. Both need each other.'

That may well be true, but what do they need each other for? Mutual growth and enhanced prosperity? Or are Euda looking for anyone at all who will help them, and ended up with a company that has taken 2 years not to raise a penny for Valirx is the only taker? Were Theorem the only suitors or were they worthy winners after a stiff competitive process? Is it Travolta meets ONJ in Grease? Or the last two on the dance floor when the lights came on? As I say, look at all sides, not just the one that looks most reassuring.

The thing that (generally) makes a share rise and stay high is revenue, which is why AIM shares are often so volatile as they spike on getting money and then fade back as the thrill wears off. The difference with SCLP is that it is not on the verge of bankruptcy but equally hasn't (yet) got sustained income from a product. The fact the SP is languishing doesn't bother me one iota as the science has always been compelling and now is moving up a few gears and may well be at the threshold.of a whole new and massively productive arena. I have always been an SCLP enthusiast from the research I have done and seen done by others, and the financial security which has come with Vulpes and Redmile's investment has enabled smooth and untroubled progress to today's RNS information. It is worth noting the very conspicuous absence of a number of posters who would dance all over the slightest hint of lack of progress to try to force a down trend on which to trade, while reasonably secure in the knowledge or hope of good news to trade over and then celebrate an optimistic trend. I've spent a long time here (like many) being somewhat irritated by the liars and manipulators who kick around, but am very much looking forward to the next 6 to 12 months as we may well now see arrive what I have always believed may come.

All the 'lifestyle company' '5p looming' and other doom mongering vermin can basically go and boil their heads.

Now wait for one or two to pop up all offended and giving it 'did you mean me?'

I'm sure they can work it out.

Looking forward to any interesting snippets from the AGM tomorrow, and I'm sure I speak for many when I say how grateful those who can't attend are to Botski if he can provide followers with a recording of the event.

'...if the deal comes off with the bits and pieces associated I think that she will have more than earned her salary....'

If.

And if it doesn't? If she puts a gun to shareholders' heads and says 'support the placing or it's curtains'?

There is a lot of pondering of 'if the merger goes ahead' and 'if the money comes through' and 'if anyone is interested' in a lot of projects that haven't yielded a single peer review or rattle of small change. As investors it is always worth looking at both sides of the 'if' before spending hard earned cash.

...in certain places today, judging by the usual good news absences.

'The Phase 2 part of the adapted trial should take 18 months and will likely generate significant partner interest.'

That's excellent - not bad for a 'lifestyle company.'